Therapy of West Nile virus infection

Canadian Journal of Neurological Sciences

Volumn 31, Issue 2, 2004, Pages 131-134

  Jackson, Alan C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; AVI 4020; BETA INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INTERFERON; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OMR IGG AM; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADOPTIVE TRANSFER; ADULT; AGED; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; EDITORIAL; ENCEPHALITIS; ENCEPHALOMYELITIS; FEMALE; GENE TARGETING; HEPATITIS C; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; VIRUS ENCEPHALITIS; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

EID: 2642523916     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100053749     Document Type: Editorial

References (46)

1. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001;344:1807-1814.
2. Pepperell C, Rau N, Krajden S, et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. Can Med Assoc J 2003;168: 1399-1405.
3. Li J, Loeb JA, Shy ME, et al. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol 2003;53:703-710.
4. Sejvar JJ, Leis AA, Stokic DS, et al. Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis 2003;9:788-793.
5. Johnson RT, Cornblath DR. Poliomyelitis and flaviviruses (Editorial). Ann Neurol 2003;53:691-692.
6. Gilad R, Lampl Y, Sadeh M, Paul M, Dan M. Optic neuritis complicating West Nile virus meningitis in a young adult. Infection 2003;31:55-56.
7. Solomon T, Fisher AF, Beasley DW, et al. Natural and nosocomial infection in a patient with West Nile encephalitis and extrapyramidal movement disorders. Clin Infect Dis 2003;36:E140-E145.
8. Sejvar JJ, Haddad MB, Tiemey BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003;290:511-515.
9. Sayao A-L, Patry D, Suchowersky O, et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci 2004;31:194-203.
10. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-1009.
11. Crotty S, Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect 2002;4:1301-1307.
12. Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001;12:261-272.
13. Jordan I, Briese T, Fischer N, Lau JY, Lipkin WI. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000;182:1214-1217.
14. Ferrara EA, Oishi JS, Wannemacher RW Jr, Stephen EL. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother 1981;19:1042-1049.
15. Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002;55:107-116.
16. Crumpacker C, Bubley G, Lucey D, Hussey S, Connor J. Ribavirin enters cerebrospinal fluid (Letter). Lancet 1986;2:45-46.
17. Tomoda A, Nomura K, Shiraishi S, et al. Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan. Brain Dev 2003;25:514-517.
18. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001;7:675-678.
19. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002;71:565-581.
20. Despres P, Griffin JW, Griffin DE. Antiviral activity of alpha interferon in Sindbis virus-infected cells is restored by anti-E2 monoclonal antibody treatment. J Virol 1995;69:7345-7348.
21. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002;8:107-108.
22. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection (Editorial). J Infect Dis 2003;188:1-4.
23. Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003;361:821-826.
24. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985;37:85-88.
25. Hara S, Kimura H, Hoshino Y, et al. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev 2003;25:367-369.
26. Brooks TJ, Phillpotts RJ. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res 1999;41:57-64.
27. Goldschmidt D. FDA gives nod to West Nile trial therapy. CNN.com/Health. August 22, 2002. Available at http://edition.cnn.com/2002/HEALTH/conditions/8/21/west.nile.drugs/index.html (accessed on March 1, 2004).
28. Camenga DL, Nathanson N, Cole GA. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis 1974;130:634-641.
29. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 2001;7:714-721.
30. Tesh RB, Arroyo J, Travassos da Rosa AP, et al. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 2002;8:1392-1397.
31. Ben Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003;188:5-12.
32. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003;77:2578-2586.
33. Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003;77:12941-12949.
34. Griffin D, Levine B, Tyor W, Ubol S, Despres P. The role of antibody in recovery from alphavirus encephalitis. Immunol Rev 1997;159:155-161.
35. Levine B, Hardwick JM, Trapp BD, et al. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991;254:856-860.
36. Dietzschold B, Kao M, Zheng YM, et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci USA 1992;89:7252-7256.
37. Kimura T, Griffin DE. Extensive immune-mediated hippocampal damage in mice surviving infection with neuroadapted Sindbis virus. Virology 2003;311:28-39.
38. Rammohan KW, McFarland HF, McFarlin DE. Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin. Nature 1981;290:588-589.
39. Seamer JH, Boulter EA, Zlotnik I. Delayed onset of encephalitis in mice passively immunised against Semliki Forest virus. Br J Exp Pathol 1971;52:408-414.
40. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin (Letter). Emerg Infect Dis 2001;7:759.
41. Hamdan A, Green P, Mendelson E, et al. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile encephalitis. Transplant Infectious Disease 2002;4:160-162.
42. Haley M, Retter AS, Fowler D, Gea-Banacloche J, O'Grady NP. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis 2003;37:e88-e90.
43. Manning A. Experimental West Nile drugs begin clinical trials. USA Today Final:D.10. September 9, 2003. Available at http://pqasb.pqarchiver.com/USAToday/402127301.html?did=402127301&FMT= ABS&FMTS=FT&date=Sep+9,+2003&desc= Experimental+West+Nile+drugs+begin+clinical+studies (accessed on March 1, 2004).
44. Smith AW, Matson DO, Stein DA, et al. Antisense treatment of caliciviridae: an emerging disease agent of animals and humans. Curr Opin Mol Ther 2002;4:177-184.
45. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001;285:193-199.
46. Medina J, Garci-Buey L, Moreno-Monteagudo JA, Trapero-Marugan M, Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003;60:135-143.